Submucosal Lidocaine Injection in Colonic Endoscopic Submucosal Dissection: A Single-Center, Double-Blind, Randomized Controlled Trial.

Dig EndoscSep 1, 2026
Clinical ResearchGastroenterologyOpen access

Tomoya Ueda, Takashi Kanesaka, Yoshiaki Ando et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-center, double-blind, randomized controlled trial evaluated the efficacy and safety of submucosal lidocaine injection during colonic endoscopic submucosal dissection (ESD) in 110 patients. While the median procedure time was shorter in the lidocaine group (67.5 vs. 78.0 min), this difference was not statistically significant (p = 0.114).

Key findings

  • Severe spasms occurred less frequently in the lidocaine group (34.6% vs. 74.1%).
  • The lidocaine group had a median of 1 antispasmodic administration compared to 2 in the control group.
  • Operator satisfaction scores were higher in the lidocaine group (median, 4.0 vs. 2.5).
  • En bloc and R0 resection rates were 100% and 84.6% in the lidocaine group, respectively.

Why it matters

Colonic spasms can complicate endoscopic procedures, impacting visualization and maneuverability. This study suggests that submucosal lidocaine may help reduce spasms and improve operator satisfaction, potentially enhancing procedural efficiency.

Source

PubMed · PMID 42666074Free full text on PubMed Central

Published in Dig Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.